{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:25:04Z","timestamp":1791908704439,"version":"4.3.4"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1097\/ypg.0b013e3283328dcd","type":"journal-article","created":{"date-parts":[[2009,10,27]],"date-time":"2009-10-27T07:16:22Z","timestamp":1256627782000},"page":"305-311","source":"Crossref","is-referenced-by-count":30,"title":["Association study of serotonergic gene variants with antipsychotic-induced adverse reactions"],"prefix":"10.1097","volume":"19","author":[{"given":"Ismail","family":"Al-Janabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Arranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra I.F.","family":"Blakemore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar A.","family":"Saiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret T.","family":"Susce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.A.","family":"Glaser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"de Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210213","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/sj.mp.4002009","article-title":"Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research","volume":"12","author":"Arranz","year":"2007","journal-title":"Mol Psychiatry"},{"key":"R2-3-20210213","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00004714-199506000-00010","article-title":"Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia","volume":"15","author":"Arthur","year":"1995","journal-title":"J Clin Psychopharmacol"},{"key":"R3-3-20210213","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/sj.ijo.0801253","article-title":"5-HT2A receptor gene polymorphism is associated with food and alcohol intake in obese people","volume":"24","author":"Aubert","year":"2000","journal-title":"Int J Obes Relat Metab Disord"},{"key":"R4-3-20210213","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.schres.2006.01.010","article-title":"Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta-analysis","volume":"83","author":"Bakker","year":"2006","journal-title":"Schizophr Res"},{"key":"R5-3-20210213","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/sj.mp.4000847","article-title":"Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia","volume":"6","author":"Basile","year":"2001","journal-title":"Mol Psychiatry"},{"key":"R6-3-20210213","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/S0140-6736(02)11706-5","article-title":"759C\/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain","volume":"360","author":"Basile","year":"2002","journal-title":"Lancet"},{"key":"R7-3-20210213","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4088\/JCP.v66n0103","article-title":"The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation","volume":"66","author":"De Leon","year":"2005a","journal-title":"J Clin Psychiatry"},{"key":"R8-3-20210213","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/01.jcp.0000177546.34799.af","article-title":"Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness","volume":"25","author":"De Leon","year":"2005b","journal-title":"J Clin Psychopharmacol"},{"key":"R9-3-20210213","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/j.1440-1681.1996.tb01154.x","article-title":"Influence of pharmacogenetics on drug disposition and response","volume":"23","author":"Eichelbaum","year":"1996","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"R10-3-20210213","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/(SICI)1096-8628(20000403)96:2<187::AID-AJMG13>3.0.CO;2-8","article-title":"Association of dopamine D3-receptor gene variants with neuroleptic-induced akathisia in schizophrenic patients: a generalization of Steen's study on DRD3 and tardive dyskinesia","volume":"96","author":"Eichhammer","year":"2000","journal-title":"Am J Med Genet"},{"key":"R11-3-20210213","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/ajmg.b.20169","article-title":"Weight gain associated with the -759C\/T polymorphism of the 5HT2C receptor and olanzapine","volume":"134","author":"Ellingrod","year":"2005","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"R12-3-20210213","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00213-006-0622-x","article-title":"Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients","volume":"190","author":"Gunes","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"R14-3-20210213","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0924-9338(03)00005-1","article-title":"Tardive dyskinesia is not associated with the polymorphisms of 5-HT2A receptor gene, serotonin transporter gene and catechol-o-methyltransferase gene","volume":"18","author":"Herken","year":"2003","journal-title":"Eur Psychiatry"},{"key":"R15-3-20210213","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00008571-200104000-00010","article-title":"Genetic variants of the serotonin system and weight change during clozapine treatment","volume":"11","author":"Hong","year":"2001","journal-title":"Pharmacogenetics"},{"key":"R16-3-20210213","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00041444-200309000-00005","article-title":"Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients","volume":"13","author":"Inada","year":"2003","journal-title":"Psychiatr Genet"},{"key":"R17-3-20210213","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1017\/S1461145704004614","article-title":"Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment","volume":"7","author":"Lattuada","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"R19-3-20210213","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0893-133X(02)00293-2","article-title":"Pharmacogenetics of tardive dyskinesia. Combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism","volume":"27","author":"Lerer","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"R20-3-20210213","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1017\/S1461145705005389","article-title":"Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype","volume":"8","author":"Lerer","year":"2005","journal-title":"Int J Neuropsychopharmacol"},{"key":"R18-3-20210213","doi-asserted-by":"crossref","first-page":"85","DOI":"10.31887\/DCNS.2006.8.1\/blerer","article-title":"Pharmacogenetics of antipsychotic therapy: pivotal research issues and the prospects for clinical implementation","volume":"8","author":"Lerer","year":"2006","journal-title":"Dialogues Clin Neurosci"},{"key":"R21-3-20210213","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1126\/science.274.5292.1527","article-title":"Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region","volume":"274","author":"Lesch","year":"1996","journal-title":"Science"},{"key":"R22-3-20210213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"R23-3-20210213","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000077360","article-title":"Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients","volume":"49","author":"Liou","year":"2004","journal-title":"Neuropsychobiology"},{"key":"R24-3-20210213","doi-asserted-by":"crossref","first-page":"s106","DOI":"10.1016\/S0893-133X(99)00046-9","article-title":"The role of serotonin in antipsychotic drug action","volume":"21","author":"Meltzer","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"R25-3-20210213","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.pnpbp.2003.09.010","article-title":"Serotonin receptors: their key role in drugs to treat schizophrenia","volume":"27","author":"Meltzer","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R26-3-20210213","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ajmg.b.30115","article-title":"Clozapine-induced weight gain associated with the 5-HT2C receptor -759-C\/T polymorphism","volume":"133B","author":"Miller","year":"2005","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"R27-3-20210213","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs","volume":"10","author":"Miyamoto","year":"2005","journal-title":"Mol Psychiatry"},{"key":"R28-3-20210213","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1210\/jc.2005-1654","article-title":"The metabolic syndrome is associated with reduced central serotonergic responsivity in healthy community volunteers","volume":"91","author":"Muldoon","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R29-3-20210213","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1176\/appi.ajp.160.4.677","article-title":"Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain","volume":"160","author":"Reynolds","year":"2003","journal-title":"Am J Psychiatry"},{"key":"R30-3-20210213","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00004850-200203000-00006","article-title":"Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: a case-control study using spontaneous reports","volume":"17","author":"Schillevoort","year":"2002","journal-title":"Int Clin Psychopharmacol"},{"key":"R31-3-20210213","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/archpsyc.1982.04290040080014","article-title":"Research diagnoses for tardive dyskinesia","volume":"39","author":"Schooler","year":"1982","journal-title":"Arch Gen Psychiatry"},{"key":"R32-3-20210213","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/sj.mp.4000249","article-title":"Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients","volume":"2","author":"Steen","year":"1997","journal-title":"Mol Psychiatry"},{"key":"R33-3-20210213","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4088\/JCP.v66n0203","article-title":"Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey","volume":"66","author":"Susce","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R34-3-20210213","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0006-3223(01)01076-9","article-title":"Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor","volume":"50","author":"Tan","year":"2001","journal-title":"Biol Psychiatry"},{"key":"R35-3-20210213","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/01213011-200504000-00002","article-title":"Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis","volume":"15","author":"Templeman","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"R36-3-20210213","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00041444-200409000-00003","article-title":"Lack of association between the -759C\/T polymorphism of the 5-HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals","volume":"14","author":"Theisen","year":"2004","journal-title":"Psychiatr Genet"},{"key":"R37-3-20210213","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/sj.mp.4001789","article-title":"Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531","volume":"11","author":"Wendland","year":"2006","journal-title":"Mol Psychiatry"},{"key":"R38-3-20210213","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/sj.mp.4001052","article-title":"Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia","volume":"7","author":"Zhang","year":"2002","journal-title":"Mol Psychiatry"},{"key":"R39-3-20210213","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/bioinformatics\/18.12.1694","article-title":"Genecounting: haplotype analysis with missing genotypes","volume":"18","author":"Zhao","year":"2002","journal-title":"Bioinformatics"},{"key":"R40-3-20210213","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/sj.mp.4001525","article-title":"SNP and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene provide evidence for association with major depression","volume":"9","author":"Zill","year":"2004a","journal-title":"Mol Psychiatry"},{"key":"R41-3-20210213","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.biopsych.2004.07.015","article-title":"Single nucleotide polymorphism and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene in suicide victims","volume":"56","author":"Zill","year":"2004b","journal-title":"Biol Psychiatry"}],"container-title":["Psychiatric Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00041444-200912000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T01:28:04Z","timestamp":1618277284000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00041444-200912000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/ypg.0b013e3283328dcd","relation":{},"ISSN":["0955-8829"],"issn-type":[{"value":"0955-8829","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}